By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Amicus Therapeutics, Inc. 

1 Cedar Brook Drive

Cranbury  New Jersey  08512  U.S.A.
Phone: 609-662-2000 Fax: 609-662-2001


SEARCH JOBS

Amicus Therapeutics is a global biotechnology company at the forefront of therapies for rare and orphan diseases. We have a unique set of platform technologies and medicines in development for people living with rare and devastating diseases, including the Lysosomal Storage Disorders Fabry disease and Pompe disease, as well as the genetic connective skin disorder Epidermolysis Bullosa (EB).

The needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. Our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers.


Key Statistics


Email: info@amicusrx.com
Ownership: Public

Web Site: Amicus
Employees: 100
Symbol: FOLD
 









Company News
Amicus (FOLD) Announces Approval For Galafold (Migalastat) For Treatment Of Fabry Disease In Australia 8/16/2017 10:35:44 AM
Amicus (FOLD) Announces Second Quarter 2017 Financial Results And Corporate Updates 8/7/2017 12:09:43 PM
Amicus (FOLD) To Announce Second Quarter 2017 Financial Results On August 7, 2017 7/25/2017 11:38:39 AM
Amicus (FOLD) Announces Closing Of Underwritten Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares 7/18/2017 10:47:09 AM
Amicus (FOLD) Prices Underwritten Offering Of Common Stock 7/13/2017 8:03:11 AM
Groundbreaking: Amicus (FOLD) Surges as the FDA Changes Its Tune on Fabry Disease Drug 7/11/2017 5:44:56 AM
Amicus (FOLD) Submits Japanese New Drug Application For Migalastat For Fabry Disease 6/28/2017 9:13:54 AM
Amicus (FOLD) Receives Rare Pediatric Disease Designation For SD-101 For Patients With Epidermolysis Bullosa 5/31/2017 10:41:11 AM
Amicus (FOLD) Announces Planned Analysis Of Primary Endpoints In Phase III Epidermolysis Bullosa Study 5/19/2017 7:43:30 AM
Amicus (FOLD) Announces Positive Functional Data From Initial Patients In Pompe Phase I/II Study 5/15/2017 8:58:19 AM
12345678910...
//-->